INREBIC® (fedratinib) is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
X
The page you are trying to access is not available.
You may have accessed this page via an outdated link or typed the URL incorrectly.